Diomed (AMEX:DIO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Diomed Charts. Click Here for more Diomed Charts.](/p.php?pid=staticchart&s=A%5EDIO&p=8&t=15)
Diomed, Inc., a subsidiary of Diomed Holdings, Inc. (AMEX: DIO), a
leading developer and marketer of minimally invasive medical
technologies, today announced that on November 20, 2006, Judge Maxine
Chesney of the United States Federal District Court for the Northern
District of California has issued a ‘Markman’
order construing the meaning of certain language in a series of patent
claims asserted against Diomed by VNUS Medical Technologies, Inc.
In July 2005, VNUS Medical Technologies, Inc. filed a lawsuit against
Diomed in the United States District Court for the Northern District of
California alleging infringement of four of its U.S. patents. Diomed
filed responses denying the allegations of infringement, and
counterclaiming against VNUS for a declaration that none of the patents
are infringed, that they are all invalid, and that two of VNUS' patents
are unenforceable for inequitable conduct. In October 2005, VNUS served
an amended complaint adding AngioDynamics, Inc. and Vascular Solutions,
Inc., as defendants. The Company is now proceeding with the discovery
phase of this litigation. The court conducted a Markman hearing on
October 30, 2006.
“In Markman hearings such as these, judges
offer interpretations of patent claims in order to provide the jury a
yardstick with which to clarify ambiguous language within a patent,”
commented David Swank, CFO of Diomed Holdings, Inc. “This
claim construction ruling clears the way for Diomed to proceed with its
defenses that the VNUS patents are not infringed by Diomed’s
EVLT® methodology and, further, that the VNUS
patents-in-suit are deficient and should be struck down.”
Diomed anticipates filing, at an appropriate time in 2007, motions for
summary judgment of non-infringement and invalidity. Summary judgment
motions require that the judge determine whether certain issues can be
resolved by the court as a matter of law without the need for trial.
About Diomed
Diomed develops and commercializes minimal and micro-invasive medical
procedures that use its proprietary laser technologies and disposable
products. Diomed’s EVLT®
laser vein ablation procedure is used in varicose vein treatments.
Diomed also provides photodynamic therapy (PDT) for use in cancer
treatments, and dental and general surgical applications. The EVLT®
procedure and the Company’s related products
were cleared by the United States FDA in January of 2002. Along with
lasers and single-use procedure kits for its EVLT®
laser vein treatment, the Company provides its customers with state of
the art physician training and practice development support. Additional
information is available on the Company’s
website: www.evlt.com.
EVLT® is a registered trademark of Diomed
Inc., Andover, MA.
Safe Harbor statements under the Private Securities Litigation Reform
Act of 1995: Statements in this news release looking forward in time
involve risks and uncertainties, including the risks associated with
trends in the products markets, reliance on third party distributors in
various countries outside the United States, reoccurring orders under
OEM contracts, market acceptance risks, technical development risks and
other risk factors. These statements relate to our future plans,
objectives, expectations and intentions. These statements may be
identified by the use of words such as "may," "will," "should,"
"potential," "expects," "anticipates," "intends," "plans," "believes"
and similar expressions. These statements are based on our current
beliefs, expectations and assumptions and are subject to a number of
risks and uncertainties. Our actual results could differ materially from
those discussed in these statements. Our Annual Report on Form SEC
10-KSB/A (the "Annual Report") contains a discussion of certain of the
risks and uncertainties that affect our business. We refer you to the
"Risk Factors" on pages 23 through 38 of the Annual Report for a
discussion of certain risks, including those relating to our business as
a medical device company without a significant operating record and with
operating losses, our risks relating to our commercialization of our
current and future products and applications and risks relating to our
common stock and its market value. Diomed disclaims any obligation or
duty to update or correct any of its forward-looking statements.
Diomed, Inc., a subsidiary of Diomed Holdings, Inc. (AMEX: DIO), a
leading developer and marketer of minimally invasive medical
technologies, today announced that on November 20, 2006, Judge Maxine
Chesney of the United States Federal District Court for the Northern
District of California has issued a 'Markman' order construing the
meaning of certain language in a series of patent claims asserted
against Diomed by VNUS Medical Technologies, Inc.
In July 2005, VNUS Medical Technologies, Inc. filed a lawsuit
against Diomed in the United States District Court for the Northern
District of California alleging infringement of four of its U.S.
patents. Diomed filed responses denying the allegations of
infringement, and counterclaiming against VNUS for a declaration that
none of the patents are infringed, that they are all invalid, and that
two of VNUS' patents are unenforceable for inequitable conduct. In
October 2005, VNUS served an amended complaint adding AngioDynamics,
Inc. and Vascular Solutions, Inc., as defendants. The Company is now
proceeding with the discovery phase of this litigation. The court
conducted a Markman hearing on October 30, 2006.
"In Markman hearings such as these, judges offer interpretations
of patent claims in order to provide the jury a yardstick with which
to clarify ambiguous language within a patent," commented David Swank,
CFO of Diomed Holdings, Inc. "This claim construction ruling clears
the way for Diomed to proceed with its defenses that the VNUS patents
are not infringed by Diomed's EVLT(R) methodology and, further, that
the VNUS patents-in-suit are deficient and should be struck down."
Diomed anticipates filing, at an appropriate time in 2007, motions
for summary judgment of non-infringement and invalidity. Summary
judgment motions require that the judge determine whether certain
issues can be resolved by the court as a matter of law without the
need for trial.
About Diomed
Diomed develops and commercializes minimal and micro-invasive
medical procedures that use its proprietary laser technologies and
disposable products. Diomed's EVLT(R) laser vein ablation procedure is
used in varicose vein treatments. Diomed also provides photodynamic
therapy (PDT) for use in cancer treatments, and dental and general
surgical applications. The EVLT(R) procedure and the Company's related
products were cleared by the United States FDA in January of 2002.
Along with lasers and single-use procedure kits for its EVLT(R) laser
vein treatment, the Company provides its customers with state of the
art physician training and practice development support. Additional
information is available on the Company's website: www.evlt.com.
EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: Statements in this news release looking forward in
time involve risks and uncertainties, including the risks associated
with trends in the products markets, reliance on third party
distributors in various countries outside the United States,
reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These statements
relate to our future plans, objectives, expectations and intentions.
These statements may be identified by the use of words such as "may,"
"will," "should," "potential," "expects," "anticipates," "intends,"
"plans," "believes" and similar expressions. These statements are
based on our current beliefs, expectations and assumptions and are
subject to a number of risks and uncertainties. Our actual results
could differ materially from those discussed in these statements. Our
Annual Report on Form SEC 10-KSB/A (the "Annual Report") contains a
discussion of certain of the risks and uncertainties that affect our
business. We refer you to the "Risk Factors" on pages 23 through 38 of
the Annual Report for a discussion of certain risks, including those
relating to our business as a medical device company without a
significant operating record and with operating losses, our risks
relating to our commercialization of our current and future products
and applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct
any of its forward-looking statements.